Results 51 to 60 of about 284,307 (179)

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network [PDF]

, 2013
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
A Bashey, A Eckert, A Ribas, AA Sarnaik, Armin Justich, AV Maker, AV Maker, Axel Hauschild, Beatrice Schuler-Thurner, C Robert, Carmen Loquai, Carola Berking, Caroline J. Voskens, Caroline Robert, Christina Klein, Christine Mateus, Claus Garbe, Clemens L. Bockmeyer, Daniela Göppner, Dirk Schadendorf, F Bompaire, F Fadel, F Torino, FS Hodi, FS Hodi, G Berthod, G Borodic, G Graziani, G Graziani, G Hunter, G Hunter, Gerold Schuler, Gheorghe Hundorfean, GQ Phan, GY Ku, H Gogas, H Tlaskalova-Hogenova, H. Peter Soyer, HB Wang, Imke Satzger, J Delyon, JA Blansfield, JD Wolchok, JD Wolchok, Jens Ulrich, JJ Nordlund, JM Kirkwood, JS Weber, JS Weber, JS Weber, Julia Vaubel, K Harmankaya, K Sanderson, Katharina C. Kaehler, KD Chmiel, KE Beck, L Min, LM Heinzerling, Lucie M. Heinzerling, Marc Schlaeppi, Michael Fluck, OP Hamnvik, P Attia, PA Prieto, Patrik Weder, Peter Mohr, Ralf Gutzmer, Reinhard Dummer, RH Friedline, Roger von Moos, Rüdiger Hein, S Bhatia, S Wilgenhof, S Wilgenhof, S Wilgenhof, SG Downey, Simone M. Goldinger, SM Liu, Stephan Grabbe, Sylvie Paetzold, T Bakacs, T Matsui, Tabea Wilhelm, Tanja Bergmann, Thomas Eigentler, Ullrich Keller, Uwe Trefzer, WB Breunis, WV Vogel   +88 more
core   +4 more sources

Effects of HMGA2 on migration and proliferation of leptomeningeal metastatic melanoma [PDF]

Zhongguo aizheng zazhi
Background and purpose: Leptomeningeal metastasis is a form of central nervous system metastasis of melanoma. High mobility group A2 (HMGA2) has been proven to play an important role in the occurrence and development of various tumors, but its biological
LI Xiaohui, ZHAO Jiaxu, PENG Haibao, ZHANG Ye, ZENG Rui, CHI Yudan
doaj   +1 more source

Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and b1-integrin activation [PDF]

, 2018
Lymphatic invasion and lymph node metastasis correlate with poor clinical outcome in melanoma. However, the mechanisms of lymphatic dissemination in distant metastasis remain incompletely understood.
Alve, S, Balistreri, G, Gramolelli, S, Hautaniemi, S, Icay, K, Ivaska, J, Lehti, K, Niiranen, O, Ojala, PM, Paatero, I, Pekkonen, P, Perälä, N, Repo, P, Saharinen, P, Taiwo, A, Tatti-Bugaeva, O, Tuohinto, K, Zinovkina, N   +17 more
core   +1 more source

Evaluation of melanin-targeted radiotherapy in combination with radiosensitizing drugs for the treatment of melanoma [PDF]

, 2014
The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. An [131I]-labeled benzamide - [131I]MIP-1145 - selectively targets melanin, reduces melanoma tumor burden and increases survival in preclinical ...
Babich, John, Boyd, Marie, Hutchison, Sharon, Mairs, Robert, Rae, Colin, Tesson, Mathias   +5 more
core   +1 more source

Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses

Clinical Medicine Insights: Case Reports, 2017
By the recent introduction of molecular targeting drugs against BRAF mutation and immune checkpoint inhibitors, the prognosis of patients with melanoma in advanced stage is now improving, but still in the minority.
W. Omata, A. Tsutsumida, K. Namikawa, A. Takahashi, K. Oashi, N. Yamazaki   +5 more
doaj   +1 more source

Harnessing autophagy to overcome mitogen‐activated protein kinase kinase inhibitor‐induced resistance in metastatic melanoma [PDF]

, 2019
Background Patients with malignant melanoma often relapse after treatment with BRAF and/or mitogen‐activated protein kinase kinase (MEK) inhibitors (MEKi) owing to development of drug resistance.
Alexander, M., Chaudhry, B., Edwards, N., Hill, David, Lovat, P.E., Plummer, R., Verykiou, S.   +6 more
core   +1 more source

Metastatic melanoma [PDF]

CA: A Cancer Journal for Clinicians, 2020
Ragini R, Kudchadkar, Michael C, Lowe, Mohammad K, Khan, Stephanie M, McBrien   +3 more
openaire   +4 more sources

Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]

, 2020
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia, Consoli, Francesca, Monti, Matilde, Vermi, William, Vescovi, Raffaella   +4 more
core   +2 more sources

Primary dermal melanoma in a patient with a history of multiple malignancies: a case report with molecular characterization [PDF]

, 2013
Introduction: Primary dermal melanoma (PDM) is a recently described clinical entity accounting for less than 1% of all melanomas. Histologically, it is located in the dermis or subcutaneous tissue, and it shows no connections with the overlying epidermis.
Colombino, Maria, Cossu, Antonio, Gulino, Marcello, Lissia, Amelia, Maxia, Sara, Paliogiannis, Panagiotis, Palmieri, Giuseppe, Palomba, Grazia, Rubino, Corrado, Sini, Germana   +9 more
core   +2 more sources

Metastatic melanoma of the gallbladder [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction. Malignant melanoma is a tumor of the melanocytes and is one of the most aggressive tumors. In most cases, the first symptoms appear in the metastatic phase of the disease. In clinical practice, malignant melanoma very rarely metastasizes to
Ninić Aleksandar, Stankić Dunja, Grubor Nikola, Mitrović-Jovanović Milica, Grubor Nikica   +4 more
doaj   +1 more source